HZ-V068 / HealZen Therap - LARVOL DELTA

HZ-V068, an oral, highly potent pan-Ras molecular glue inhibitor demonstrated robust potency in pancreatic ductal adenocarcinoma and colorectal cancer models (AACR 2025) - "RMC6236, a next generation of novel pan-RasMulti(on) inhibitor which functions as molecular glue to form binary complex with CYPA and RasMulti and sterically blocks Ras binding to effectors, has been validated as a superior strategy targeting Ras in clinical study. In summary, HZ-V068 is a promising targeted therapeutic option for PDAC and CRC. Based on these promising results, we are advancing HZ-V068 into clinical study."

Preclinical • Colorectal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • BRAF • KRAS